Targeting CDK2 should therefore be considered with caution but has promise of becoming a therapeutic avenue that might offset tumor resistance to CDK4 inhibition, which CCNE1 amplifications normally confer to [22]. The gene discussed is CDK2; the disease is neoplasm.